- Home
- MERC vs BDTX Comparison
MERC vs BDTX Comparison
Compare MERC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- BDTX
- Stock Information
- Founded
- MERC 1968
- BDTX 2014
- Country
- MERC Canada
- BDTX United States
- Employees
- MERC N/A
- BDTX N/A
- Industry
- MERC Paper
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MERC Basic Materials
- BDTX Health Care
- Exchange
- MERC Nasdaq
- BDTX Nasdaq
- Market Cap
- MERC 190.9M
- BDTX 181.4M
- IPO Year
- MERC 1987
- BDTX 2020
- Fundamental
- Price
- MERC $2.60
- BDTX $3.95
- Analyst Decision
- MERC Hold
- BDTX Strong Buy
- Analyst Count
- MERC 3
- BDTX 5
- Target Price
- MERC $4.67
- BDTX $10.40
- AVG Volume (30 Days)
- MERC 503.8K
- BDTX 933.6K
- Earning Date
- MERC 11-06-2025
- BDTX 11-05-2025
- Dividend Yield
- MERC 8.62%
- BDTX N/A
- EPS Growth
- MERC N/A
- BDTX N/A
- EPS
- MERC N/A
- BDTX 0.25
- Revenue
- MERC $1,951,044,000.00
- BDTX $70,000,000.00
- Revenue This Year
- MERC N/A
- BDTX N/A
- Revenue Next Year
- MERC $13.33
- BDTX N/A
- P/E Ratio
- MERC N/A
- BDTX $15.78
- Revenue Growth
- MERC N/A
- BDTX N/A
- 52 Week Low
- MERC $2.37
- BDTX $1.20
- 52 Week High
- MERC $8.28
- BDTX $4.45
- Technical
- Relative Strength Index (RSI)
- MERC 43.70
- BDTX 54.71
- Support Level
- MERC $2.37
- BDTX $3.88
- Resistance Level
- MERC $2.72
- BDTX $4.06
- Average True Range (ATR)
- MERC 0.12
- BDTX 0.26
- MACD
- MERC 0.02
- BDTX -0.05
- Stochastic Oscillator
- MERC 47.66
- BDTX 33.33
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.